Enovis (ENOV) Expected to Announce Quarterly Earnings on Thursday

Enovis (NYSE:ENOV) is projected to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of $0.81 per share and revenue of $584.30 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Enovis Stock Up 2.1%

ENOV stock opened at $22.08 on Thursday. Enovis has a 52 week low of $21.00 and a 52 week high of $44.76. The business has a 50-day simple moving average of $24.77 and a 200 day simple moving average of $28.39. The company has a quick ratio of 1.16, a current ratio of 2.22 and a debt-to-equity ratio of 0.66. The company has a market cap of $1.26 billion, a PE ratio of -0.93 and a beta of 1.52.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ENOV. UBS Group restated a “buy” rating and issued a $50.00 target price on shares of Enovis in a research report on Monday, January 5th. BTIG Research started coverage on shares of Enovis in a research report on Tuesday, January 6th. They set a “buy” rating and a $41.00 price objective for the company. Evercore reaffirmed an “outperform” rating on shares of Enovis in a report on Monday, January 12th. Canaccord Genuity Group decreased their price target on Enovis from $58.00 to $50.00 and set a “buy” rating on the stock in a research note on Wednesday, December 17th. Finally, Wells Fargo & Company upped their price objective on Enovis from $41.00 to $42.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $46.71.

Insider Buying and Selling at Enovis

In other news, insider John Kleckner bought 2,468 shares of the stock in a transaction on Tuesday, November 25th. The stock was acquired at an average price of $30.32 per share, with a total value of $74,829.76. Following the acquisition, the insider directly owned 12,302 shares in the company, valued at approximately $372,996.64. This trade represents a 25.10% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Daniel A. Pryor sold 999 shares of Enovis stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $27.20, for a total value of $27,172.80. The SEC filing for this sale provides additional information. Company insiders own 2.70% of the company’s stock.

Hedge Funds Weigh In On Enovis

A number of hedge funds and other institutional investors have recently made changes to their positions in ENOV. AQR Capital Management LLC increased its position in Enovis by 12.5% during the 1st quarter. AQR Capital Management LLC now owns 63,671 shares of the company’s stock valued at $2,363,000 after purchasing an additional 7,072 shares during the period. Goldman Sachs Group Inc. raised its stake in Enovis by 37.6% during the first quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company’s stock worth $10,226,000 after buying an additional 73,116 shares during the last quarter. Empowered Funds LLC lifted its holdings in Enovis by 13.0% in the first quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock valued at $249,000 after buying an additional 749 shares during the period. EverSource Wealth Advisors LLC boosted its position in Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after acquiring an additional 707 shares during the last quarter. Finally, Amundi grew its holdings in Enovis by 24,405.0% during the 2nd quarter. Amundi now owns 9,802 shares of the company’s stock worth $328,000 after acquiring an additional 9,762 shares during the period. 98.45% of the stock is owned by institutional investors and hedge funds.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.